CClinicalTrials.gg
Status unknownNCT04703283Updated Jan 11, 2021

Self-help Lifestyle Medicine for Insomnia

An interventional study of Lifestyle Medicine in Insomnia, sponsored by Chinese University of Hong Kong. Status unknown at 1 site in Hong Kong. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-11.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will examine the effects of a self-help smartphone-based multi-component lifestyle medicine intervention (LM) for alleviating insomnia symptoms in a Chinese population. Since a range of lifestyle factors are related to the pathogenesis and progression of insomnia, modifying different lifestyle factors simultaneously, such as diet, exercise, stress, and sleep which are empirically supported by previous reviews, may be effective to reduce insomnia symptoms (Reid et al., 2010; Vedaa et al., 2016). Traditional Chinese nutritional values will be integrated into the smartphone application to increase the acceptability towards the intervention. A prevalence study suggested that self-help interventions are preferred due to the potential stigmatization related to mental health interventions and the high cost of mental health services in Hong Kong (Lee, Tsang, \& Kwok, 2007). Nonetheless, to date, only limited self-help interventions that target lifestyle medicine for sleep-related problems are available. Through this study, we aimed to promote evidence-based patient care and improve help-seeking behaviors and access to evidence-based lifestyle interventions for insomnia.

Read the detailed description

This study will be a randomized controlled trial on the effects of a self-help smartphone-based multi-component lifestyle medicine intervention for reducing insomnia symptoms in the Chinese population. Prior to all study procedures, eligible participants will be required to complete an online informed consent (with telephone support). Assuming an alpha error of 5%, a beta error rate of 20%, and a between-group effect size of 0.77 for the Insomnia Severity Scale (Ip et al., 2020), the final sample is 28 for both groups. With an estimation of 20% withdrawal, 70 eligible participants will be randomly assigned to either the smartphone-based multi-component lifestyle medicine intervention (LM group) or the waitlist control group (WL group) in a ratio of 1:1.

02

Conditions studied

  • Insomnia

Keywords

  • Insomnia
  • Lifestyle Medicine
  • Self-help
03

In context

Sleep Initiation and Maintenance Disorders

1,855 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 593 are open to participants now.

This study's planned enrollment of 70 is close to the median of 73 across 1,631 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Hong Kong residents
  • Aged ≥ 18 years
  • Have an Insomnia Severity Index (ISI) score ≥10, indicating at least sub threshold level of insomnia symptoms are present
  • Able to read Chinese and type in Chinese or English
  • Have an Internet-enabled mobile device (iOS or Android operating system)
  • Are willing to provide informed consent and comply with the trial protocol

Exclusion criteria

Exclusion Criteria:

  • Current involvement in psychotherapy or unstable medication for sleep, depression, and/or anxiety
  • Beck Depression Inventory (BDI-II) Item 9 score of at least 2 indicating a current moderate suicidal risk that requires active crisis management (referral information to professional services will be provided to those with serious suicidal risk)
  • Are having unsafe conditions and are not recommended for exercise or a change in diet by physicians
  • Having major psychiatric, medical, or neurocognitive disorders that make participation infeasible or interfere with the adherence to the lifestyle modification
  • Other untreated sleep disorders, including narcolepsy, obstructive sleep apnoea (OSA), and restless leg syndrome (RLS)/periodic leg movement disorder (PLMD) based on the cut-off scores (≥ 7 on narcolepsy; ≥ 15 on OSA; ≥ 7 on RLS/PLMD) of individual sections in SLEEP-50
  • Shift work, pregnancy, work, family, or other commitments that interfere with regular night-time sleep patterns
  • Hospitalization
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Lifestyle Medicine Group

    Lifestyle intervention with components including exercise, diet, stress management, and sleep management

    Behavioral: Lifestyle Medicine

  • No intervention
    Waitlist Control Group

    Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment

Interventions

  • BehavioralLifestyle Medicine

    Lifestyle intervention with components including exercise, diet, stress management, and sleep management

06

What researchers measure

Primary outcomes

  1. Change in the Insomnia Severity Index (ISI)

    ISI is a 7-item scale designed to evaluate perceived insomnia severity. Ratings on the 5-point Likert scale are obtained on the perceived severity of sleep-onset, sleep-maintenance, early morning awakening problems, satisfaction with current sleep pattern, interference with daily functioning, noticeably of impairment attributed to the sleep problem, and level of distress caused by the sleep problem.

    Time frame: Baseline, immediately post-intervention, and 1-month post-intervention

Secondary outcomes

  1. Change in the Hospital Anxiety and Depression Scale (HADS)

    The HADS, a self-reporting questionnaire used for assessing the level of depressive and anxiety symptoms over the past week on a 4-point scale. The HADS consists of two parts: an anxiety subscale (HADS-A) and a depression subscale (HADS-D), both of which have seven items.

    Time frame: Baseline, immediately post-intervention, and 1-month post-intervention

  2. Change in the Short Form (Six-Dimension) Health Survey (SF-6D)

    SF-6D is a preference-based single index measure of health. A six-digit number represents each SF-6D health state, each digit denotes the level of one of six SF-6D dimensions: physical functioning, role limitation, social functioning, bodily pain, mental health, and vitality.

    Time frame: Baseline, immediately post-intervention, and 1-month post-intervention

  3. Change in the Health-Promoting Lifestyle Profile (HPLP II)

    The 52-item HPLPII is composed of a total scale and six subscales to measure behaviors in the theorized dimensions of health-promoting lifestyle: spiritual growth, interpersonal relations, nutrition, physical activity, health responsibility, and stress management.

    Time frame: Baseline, immediately post-intervention, and 1-month post-intervention

  4. Change in the Sheehan Disability Scale (SDS)

    SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.

    Time frame: Baseline, immediately post-intervention, and 1-month post-intervention

  5. Change in the Credibility-Expectancy Questionnaire (CEQ)

    The 6-item CEQ yielded ratings of treatment credibility, acceptability/satisfaction, and expectations for success.

    Time frame: Baseline, immediately post-intervention, and 1-month post-intervention

  6. Change in the Pittsburgh sleep quality index (PSQI)

    Participants' subjective sleep disturbance over the past month will be assessed using PSQI. PSQI consists of 19 self-rating items that can be categorized into seven components, including subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is scored on a 4-point Likert scale (0-3). The sum of the seven components results in a global score of 21. A high score indicates worse sleep quality.

    Time frame: Baseline, immediately post-intervention, and 1-month post-intervention

  7. Change in the Consensus Sleep Diary (CSD-M)

    The standardized sleep diary records sleep time, wake time, perceived sleeping quality, use of hypnotics, etc. on a daily basis. Variables derived from the sleep diary include sleep onset latency (SOL), wake after sleep onset (WASO), total wake time (TWT), total sleep time (TST), sleep efficiency (SE), etc.

    Time frame: Baseline, immediately post-intervention, and 1-month post-intervention

  8. Self-developed survey

    The self-developed survey will collect information including demographic information (e.g., age, gender, level of education, working industry, relationship status, and location of residence), substance use, body mass index (BMI), rest-activity pattern, and social rhythms, etc.

    Time frame: Baseline

07

Study locations

1 site
  • The Chinese University of Hong Kong
    Sha Tin, Hong Kong
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04703283
Lead sponsor
Chinese University of Hong Kong
Responsible party
Fiona YY Ho (Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Jan 11, 2021
Start date
Mar 2021 (estimated)
Primary completion
Aug 2021 (estimated)
Completion
Oct 2021 (estimated)
Last update
Jan 11, 2021

Study contacts

Vincent Wing-Hei Wong
Contact
vincentwongwh@link.cuhk.edu.hk
+852 3943 6575

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion